table of content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2022-2027)
1.4.2 East Asia Market States and Outlook (2022-2027)
1.4.3 Europe Market States and Outlook (2022-2027)
1.4.4 South Asia Market States and Outlook (2022-2027)
1.4.5 Southeast Asia Market States and Outlook (2022-2027)
1.4.6 Middle East Market States and Outlook (2022-2027)
1.4.7 Africa Market States and Outlook (2022-2027)
1.4.8 Oceania Market States and Outlook (2022-2027)
1.4.9 South America Market States and Outlook (2022-2027)
1.5 Global Radiopharmaceuticals in Nuclear Medicine Market Size Analysis from 2022 to 2027
1.5.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Analysis from 2022 to 2027 by Consumption Volume
1.5.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size Analysis from 2022 to 2027 by Value
1.5.3 Global Radiopharmaceuticals in Nuclear Medicine Price Trends Analysis from 2022 to 2027
1.6 COVID-19 Outbreak: Radiopharmaceuticals in Nuclear Medicine Industry Impact
Chapter 2 Global Radiopharmaceuticals in Nuclear Medicine Competition by Types, Applications, and Top Regions and Countries
2.1 Global Radiopharmaceuticals in Nuclear Medicine (Volume and Value) by Type
2.1.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption and Market Share by Type (2016-2021)
2.1.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue and Market Share by Type (2016-2021)
2.2 Global Radiopharmaceuticals in Nuclear Medicine (Volume and Value) by Application
2.2.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption and Market Share by Application (2016-2021)
2.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue and Market Share by Application (2016-2021)
2.3 Global Radiopharmaceuticals in Nuclear Medicine (Volume and Value) by Regions
2.3.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption and Market Share by Regions (2016-2021)
2.3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue and Market Share by Regions (2016-2021)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2016-2021 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2016-2021 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import by Regions (2016-2021)
4.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption by Regions (2016-2021)
4.2 North America Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021)
4.3 East Asia Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021)
4.4 Europe Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021)
4.5 South Asia Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021)
4.6 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021)
4.7 Middle East Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021)
4.8 Africa Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021)
4.9 Oceania Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021)
4.10 South America Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021)
Chapter 5 North America Radiopharmaceuticals in Nuclear Medicine Market Analysis
5.1 North America Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis
5.1.1 North America Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19
5.2 North America Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types
5.3 North America Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application
5.4 North America Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries
5.4.1 United States Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
5.4.2 Canada Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
5.4.3 Mexico Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
Chapter 6 East Asia Radiopharmaceuticals in Nuclear Medicine Market Analysis
6.1 East Asia Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis
6.1.1 East Asia Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19
6.2 East Asia Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types
6.3 East Asia Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application
6.4 East Asia Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries
6.4.1 China Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
6.4.2 Japan Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
6.4.3 South Korea Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
Chapter 7 Europe Radiopharmaceuticals in Nuclear Medicine Market Analysis
7.1 Europe Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis
7.1.1 Europe Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19
7.2 Europe Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types
7.3 Europe Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application
7.4 Europe Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries
7.4.1 Germany Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
7.4.2 UK Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
7.4.3 France Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
7.4.4 Italy Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
7.4.5 Russia Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
7.4.6 Spain Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
7.4.7 Netherlands Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
7.4.8 Switzerland Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
7.4.9 Poland Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
Chapter 8 South Asia Radiopharmaceuticals in Nuclear Medicine Market Analysis
8.1 South Asia Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis
8.1.1 South Asia Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19
8.2 South Asia Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types
8.3 South Asia Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application
8.4 South Asia Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries
8.4.1 India Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
8.4.2 Pakistan Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
8.4.3 Bangladesh Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
Chapter 9 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market Analysis
9.1 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis
9.1.1 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19
9.2 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types
9.3 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application
9.4 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries
9.4.1 Indonesia Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
9.4.2 Thailand Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
9.4.3 Singapore Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
9.4.4 Malaysia Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
9.4.5 Philippines Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
9.4.6 Vietnam Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
9.4.7 Myanmar Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
Chapter 10 Middle East Radiopharmaceuticals in Nuclear Medicine Market Analysis
10.1 Middle East Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis
10.1.1 Middle East Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19
10.2 Middle East Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types
10.3 Middle East Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application
10.4 Middle East Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries
10.4.1 Turkey Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
10.4.2 Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
10.4.3 Iran Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
10.4.4 United Arab Emirates Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
10.4.5 Israel Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
10.4.6 Iraq Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
10.4.7 Qatar Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
10.4.8 Kuwait Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
10.4.9 Oman Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
Chapter 11 Africa Radiopharmaceuticals in Nuclear Medicine Market Analysis
11.1 Africa Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis
11.1.1 Africa Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19
11.2 Africa Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types
11.3 Africa Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application
11.4 Africa Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries
11.4.1 Nigeria Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
11.4.2 South Africa Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
11.4.3 Egypt Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
11.4.4 Algeria Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
11.4.5 Morocco Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
Chapter 12 Oceania Radiopharmaceuticals in Nuclear Medicine Market Analysis
12.1 Oceania Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis
12.2 Oceania Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types
12.3 Oceania Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application
12.4 Oceania Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries
12.4.1 Australia Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
12.4.2 New Zealand Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
Chapter 13 South America Radiopharmaceuticals in Nuclear Medicine Market Analysis
13.1 South America Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis
13.1.1 South America Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19
13.2 South America Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types
13.3 South America Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application
13.4 South America Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Major Countries
13.4.1 Brazil Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
13.4.2 Argentina Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
13.4.3 Columbia Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
13.4.4 Chile Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
13.4.5 Venezuela Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
13.4.6 Peru Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
13.4.7 Puerto Rico Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
13.4.8 Ecuador Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021
Chapter 14 Company Profiles and Key Figures in Radiopharmaceuticals in Nuclear Medicine Business
14.1 Bracco Imaging S.P.A.
14.1.1 Bracco Imaging S.P.A. Company Profile
14.1.2 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Specification
14.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.2 Cambridge Isotope Laboratories, Inc.
14.2.1 Cambridge Isotope Laboratories, Inc. Company Profile
14.2.2 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
14.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.3 Cardinal Health, Inc.
14.3.1 Cardinal Health, Inc. Company Profile
14.3.2 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
14.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.4 Covidien, Plc
14.4.1 Covidien, Plc Company Profile
14.4.2 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Specification
14.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.5 Eczacibasi-Monrol
14.5.1 Eczacibasi-Monrol Company Profile
14.5.2 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Specification
14.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.6 Fujifilm Holdings Corporation
14.6.1 Fujifilm Holdings Corporation Company Profile
14.6.2 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Specification
14.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.7 GE Healthcare (Subsidiary Of General Electric Company)
14.7.1 GE Healthcare (Subsidiary Of General Electric Company) Company Profile
14.7.2 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Specification
14.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.8 IBA Group
14.8.1 IBA Group Company Profile
14.8.2 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Specification
14.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.9 Isotec, Inc. (Sigma-Aldrich)
14.9.1 Isotec, Inc. (Sigma-Aldrich) Company Profile
14.9.2 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Specification
14.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.10 Lantheus Medical Imaging, Inc.
14.10.1 Lantheus Medical Imaging, Inc. Company Profile
14.10.2 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
14.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.11 Nordion, Inc.
14.11.1 Nordion, Inc. Company Profile
14.11.2 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
14.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.12 Ntp Radioisotopes (Pty), Ltd.
14.12.1 Ntp Radioisotopes (Pty), Ltd. Company Profile
14.12.2 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Specification
14.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.13 Siemens Healthcare (Subsidiary Of Siemens AG)
14.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Company Profile
14.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Specification
14.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.14 Taiyo Nippon Sanso Corporation
14.14.1 Taiyo Nippon Sanso Corporation Company Profile
14.14.2 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Specification
14.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.15 Urenco Limited
14.15.1 Urenco Limited Company Profile
14.15.2 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Specification
14.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.16 Rotem Industries, Ltd., Inc.
14.16.1 Rotem Industries, Ltd., Inc. Company Profile
14.16.2 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
14.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.17 Australian Nuclear Association And Technology Organization (ANSTO)
14.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Company Profile
14.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Specification
14.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.18 Board of Radiation And Isotope Technology (BRIT)
14.18.1 Board of Radiation And Isotope Technology (BRIT) Company Profile
14.18.2 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Specification
14.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.19 Institute of Atomic Energy Polatom Radioisotope Centre
14.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Company Profile
14.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Specification
14.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.20 Institute of Isotopes Co., Ltd.
14.20.1 Institute of Isotopes Co., Ltd. Company Profile
14.20.2 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Specification
14.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.21 Institute Of Radioelement (IRE)
14.21.1 Institute Of Radioelement (IRE) Company Profile
14.21.2 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Specification
14.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
Chapter 15 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast (2022-2027)
15.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Price Forecast (2022-2027)
15.1.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption Volume and Growth Rate Forecast (2022-2027)
15.1.2 Global Radiopharmaceuticals in Nuclear Medicine Value and Growth Rate Forecast (2022-2027)
15.2 Global Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027)
15.2.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption Volume and Growth Rate Forecast by Regions (2022-2027)
15.2.2 Global Radiopharmaceuticals in Nuclear Medicine Value and Growth Rate Forecast by Regions (2022-2027)
15.2.3 North America Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.4 East Asia Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.5 Europe Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.6 South Asia Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.7 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.8 Middle East Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.9 Africa Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.10 Oceania Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.11 South America Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.3 Global Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Price Forecast by Type (2022-2027)
15.3.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption Forecast by Type (2022-2027)
15.3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Forecast by Type (2022-2027)
15.3.3 Global Radiopharmaceuticals in Nuclear Medicine Price Forecast by Type (2022-2027)
15.4 Global Radiopharmaceuticals in Nuclear Medicine Consumption Volume Forecast by Application (2022-2027)
15.5 Radiopharmaceuticals in Nuclear Medicine Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
